Transverse myelitis surgery
Jump to navigation
Jump to search
|
Transverse myelitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Transverse myelitis surgery On the Web |
|
American Roentgen Ray Society Images of Transverse myelitis surgery |
|
Risk calculators and risk factors for Transverse myelitis surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
Overview
- Surgical intervention is not recommended for treating the intrinsic, noncompressive inflammatory spinal cord lesion of transverse myelitis. There is no anatomical target for decompression, and surgery does not reverse immune-mediated spinal-cord inflammation.[1]
- Surgery may become necessary only when:
- Magnetic resonance imaging (MRI) identifies a separate extrinsic lesion causing spinal cord compression that requires cause-specific surgical treatment; or
- persistent neurological disability leads to a carefully selected complication that remains refractory to appropriate non-surgical and less-invasive management.
- No contemporary American or European guideline identifies a disease-specific operation that cures transverse myelitis. The complication-directed procedures described below are drawn from current spasticity, neuro-urology, neurogenic bowel, and wound-care guidance and must be individualized.
| Key surgical principle: A patient with presumed transverse myelitis and radiologically confirmed spinal-cord compression requires urgent evaluation of the compressive cause. The compressive lesion—not the intrinsic inflammatory myelitis—is the surgical target. |
Surgery
Acute structural lesions requiring surgical evaluation
- In patients being evaluated for transverse myelitis, MRI should distinguish intrinsic spinal-cord disease from extrinsic compression before treatment decisions are finalized.[1]
| Clinical or imaging finding | Surgical implication | Clinical guidance |
|---|---|---|
| Noncompressive inflammatory spinal-cord lesion | No decompressive operation is indicated solely for transverse myelitis. | Decompression should not be performed solely for inflammatory transverse myelitis. Disease-directed care is addressed separately in Transverse myelitis medical therapy and Transverse myelitis interventions.[1] |
| Spinal infection with compression, neurological deterioration, deformity, or instability | Urgent spine-surgical and infectious-disease assessment for decompression, debridement, drainage, and/or stabilization according to the anatomical lesion and clinical status. | For vertebral osteomyelitis, current American guidance recommends surgery for progressive neurological deficits, progressive deformity, or spinal instability despite adequate antimicrobial therapy; debridement may also be considered for persistent bloodstream infection or worsening pain despite appropriate therapy.[2] |
| Malignant spinal-cord compression | Urgent oncology and spinal-surgery assessment for decompression and/or stabilization when appropriate. | European guidance recommends offering surgery intended to halt or reverse neurological decline as soon as possible after neurological symptoms or signs of metastatic spinal-cord compression develop. Procedure selection depends on prognosis, mechanical instability, neurological status, tumor characteristics, and patient goals.[3] |
| Other extrinsic compression | Cause-specific urgent surgical assessment may be required for an epidural hematoma, severe disc herniation, spinal stenosis, traumatic instability, or another compressive mass. | Management follows the identified structural diagnosis. These conditions should not be treated as uncomplicated inflammatory transverse myelitis.[1] |
Intrathecal baclofen pump implantation
- In transverse myelitis, implantation of a programmable intrathecal baclofen (ITB) pump may be considered for severe multisegmental or generalized disabling spasticity that remains inadequately controlled or is not tolerated with less-invasive treatment.[4][5]
- A specialist multidisciplinary team should identify measurable goals and evaluate reversible aggravating factors before implantation. A screening trial should demonstrate clinically meaningful benefit without unacceptable weakness or adverse effects.
- The patient and caregivers must be able to maintain scheduled pump refills, dose adjustment, surveillance, and emergency access. Counseling must address infection, catheter migration or obstruction, pump malfunction, cerebrospinal-fluid leakage, overdose, and potentially life-threatening baclofen withdrawal.[4][5][6]
Neuro-urological surgery
- In transverse myelitis, neuro-urological surgery is reserved for selected patients with refractory neurogenic lower urinary tract dysfunction (NLUTD), unsafe bladder-storage pressures, threatened upper urinary tracts, severe incontinence, or an unsustainable method of bladder emptying.[7][8]
| Procedure | Appropriate role and essential considerations |
|---|---|
| Suprapubic catheter placement | Consider when long-term indwelling catheter drainage is unavoidable and intermittent catheterization is not feasible. American guidance favors a suprapubic rather than a chronic urethral catheter in appropriately selected patients who require permanent indwelling drainage. Continued catheter-site and urinary-tract surveillance remains necessary.[7] |
| Augmentation cystoplasty | Consider for low bladder compliance or neurogenic detrusor overactivity that remains refractory to appropriate less-invasive treatment. Before surgery, assess renal function, urodynamic risk, bowel suitability, the patient's ability to perform catheterization when required, and capacity for lifelong follow-up. Counsel about mucus production, urinary infection, stones, metabolic complications, bowel complications, perforation, and possible reoperation.[7][8] |
| Continence or bladder-outlet procedures | A urethral sling, artificial urinary sphincter, bladder-neck procedure, or outlet-reduction procedure may be considered only for a clearly defined urodynamic indication in a specialist neuro-urology center. The operative plan must preserve safe bladder-storage pressures and provide a reliable emptying strategy.[7][8] |
| Continent catheterizable channel or urinary diversion | Consider when catheterization through the urethra is not feasible, when other reconstructive approaches have failed or are inappropriate, or when diversion is required to protect the upper urinary tract and improve quality of life. Selection must account for hand function, mobility, cognition, caregiver support, bowel status, renal function, stoma care, complication burden, and the possibility of further surgery.[7][8] |
Neurogenic bowel surgery
- In transverse myelitis, bowel surgery should be considered only for severe refractory neurogenic bowel dysfunction or major bowel-management complications after an individualized conservative program and appropriate less-invasive interventions have failed.
- A Malone antegrade continence enema (MACE) procedure may be considered in carefully selected patients who can manage antegrade irrigation and understand the possibility of stomal stenosis, leakage, infection, or revision.
- Colostomy may be considered for severe refractory dysfunction, recurrent impaction, intractable incontinence, prolonged bowel-care burden, or complications such as pressure injury contamination when other approaches are unsuccessful. The decision should include colorectal surgery, rehabilitation, stoma-care education, and shared decision-making.[9]
Pressure-injury surgery
- In transverse myelitis, surgery for a pressure injury may be considered when a deep wound does not respond to appropriate wound care or when rapid durable closure is clinically required and the patient is an acceptable operative candidate.
- Surgical management may include excision of devitalized tissue, treatment of associated osteomyelitis when present, and closure by direct approximation, skin grafting, or flap reconstruction.
- Before definitive closure, optimize pressure off-loading, perfusion, nutrition, moisture and continence management, infection control, and the patient's ability to follow a postoperative positioning and recurrence-prevention plan. Bacterial balance should be achieved before surgical closure.[10]
Perioperative planning
- In transverse myelitis, every elective operation should begin with documentation of the neurological baseline, the specific functional or organ-protection goal, reasonable alternatives, and the expected postoperative care burden.
- Assess respiratory weakness, impaired sensation, skin integrity, positioning needs, venous-thromboembolism risk, bladder and bowel management, infection risk, and the potential for autonomic dysreflexia in patients with an appropriate neurological level.
- Plan postoperative rehabilitation, pressure relief, equipment, caregiver training, and specialist surveillance before discharge.
- Implanted pumps, urinary reconstruction, diversion procedures, and pressure-injury reconstruction require reliable long-term follow-up; surgery should not proceed without a sustainable aftercare pathway.[6][7][8][10]
Indications
- In transverse myelitis, potential indications for surgery include:
- A separate structural lesion causing spinal-cord compression for which decompression, drainage, debridement, tumor surgery, and/or stabilization is indicated.[2][3]
- Severe generalized or multisegmental spasticity with meaningful predefined goals, inadequate response or intolerance to less-invasive treatment, and a successful ITB screening trial.[4][5]
- Refractory NLUTD that threatens renal function, maintains unsafe bladder pressures, produces severe incontinence, or cannot be managed with an acceptable less-invasive emptying strategy.[7][8]
- Severe refractory neurogenic bowel dysfunction or bowel-related complications after failure of a structured conservative and minimally invasive program.[9]
- A deep or complicated pressure injury requiring debridement or definitive closure after appropriate wound and patient optimization.[10]
Contraindications
- In transverse myelitis, surgery should not be performed solely because an intrinsic inflammatory lesion remains visible on MRI, neurological recovery is incomplete, or severe disability persists without an independent surgically correctable target.
- Procedure-specific contraindications and reasons to defer or reconsider surgery include:
- absence of a clearly defined surgical objective or a reasonable expectation of clinically meaningful benefit;
- uncontrolled systemic or local infection for an elective implant or reconstructive procedure;
- uncorrected coagulopathy or medical instability that makes operative risk unacceptable;
- failure to complete the required specialist assessment or appropriate less-invasive treatment;
- inability to maintain essential follow-up, pump refills, catheterization, stoma care, wound off-loading, or emergency access, unless a reliable caregiver-supported plan is established;
- lack of meaningful benefit or unacceptable weakness during an ITB screening trial before pump implantation;[4][6]
- inadequate bladder evaluation or inability to sustain the required emptying and surveillance plan before urinary reconstruction;[7][8]
- untreated ischemia, uncontrolled wound infection, inadequate debridement, or absence of a postoperative pressure-relief plan before definitive pressure-injury closure.[10]
References
- ↑ 1.0 1.1 1.2 1.3 Peckham M, Hutchins TA, Amrhein TJ, et al.; Expert Panel on Neurological Imaging. ACR Appropriateness Criteria® Myelopathy: 2026 Update. Journal of the American College of Radiology. 2026;23(9):1870-1883. doi:10.1016/j.jacr.2026.06.003. PMID: 42340276.
- ↑ 2.0 2.1 Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clinical Infectious Diseases. 2015;61(6):e26-e46. doi:10.1093/cid/civ482. PMID: 26229122.
- ↑ 3.0 3.1 National Institute for Health and Care Excellence. Spinal metastases and metastatic spinal cord compression. NICE guideline NG234. Published September 6, 2023. Accessed October 5, 2026.
- ↑ 4.0 4.1 4.2 4.3 Verduzco-Gutierrez M, Raghavan P, Pruente J, et al. American Academy of Physical Medicine and Rehabilitation consensus guidance on spasticity assessment and management. PM&R. 2024;16(8):864-887. doi:10.1002/pmrj.13211. PMID: 38770827.
- ↑ 5.0 5.1 5.2 Biering-Sørensen B, Stevenson V, Bensmail D, et al. European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A. Journal of Rehabilitation Medicine. 2022;54:jrm00241. doi:10.2340/16501977-2877. PMID: 34608495.
- ↑ 6.0 6.1 6.2 Eldabe S, Duarte R, Thomson S, et al. Intrathecal drug delivery for the management of pain and spasticity in adults: British Pain Society's recommendations for best clinical practice. British Journal of Pain. Published online September 7, 2024. doi:10.1177/20494637241280356. PMID: 39552923.
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 Ginsberg DA, Boone TB, Cameron AP, et al. The American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Guideline on adult neurogenic lower urinary tract dysfunction: treatment and follow-up. The Journal of Urology. 2021;206(5):1106-1113. doi:10.1097/JU.0000000000002239. PMID: 34495688.
- ↑ 8.0 8.1 8.2 8.3 8.4 8.5 8.6 Sartori AM, Kessler TM, Ecclestone H, et al. European Association of Urology Guidelines on Neuro-urology: summary of the 2026 update. European Urology. 2026;90(3):241-253. doi:10.1016/j.eururo.2026.04.012. PMID: 42457452.
- ↑ 9.0 9.1 Johns J, Krogh K, Rodriguez GM, et al. Management of neurogenic bowel dysfunction in adults after spinal cord injury: clinical practice guideline for health care providers. Topics in Spinal Cord Injury Rehabilitation. 2021;27(2):75-151. doi:10.46292/sci2702-75. PMID: 34108835.
- ↑ 10.0 10.1 10.2 10.3 Gould LJ, Alderden J, Aslam R, et al. Wound Healing Society guidelines for the treatment of pressure ulcers—2023 update. Wound Repair and Regeneration. 2024;32(1):6-33. doi:10.1111/wrr.13130. PMID: 37970711.